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1 |  INTRODUCTION
The Global Initiative for Asthma (GINA, 2018) has defined 
asthma as a chronic respiratory and inflammatory disease with 
episodes of chest tightness, shortness of breath, wheezing and 
coughing.1 The fact that there are estimates of 300 million 
asthma patients globally, which may increase to 400 million by 
2025, demonstrates high disease prevalence.2-5 The most recent 
study (2018) in the Middle East showed some variability in dis-
ease prevalence (1%‐18%) among countries and within different 
regions in the same country. This variability may be attributed 
to differences in environmental conditions, ethnic backgrounds, 
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Abstract
Asthma is a clinical problem with social, psychological and economic burdens. To 
improve patient disease management, different education programmes have been 
developed. Challenges in asthma management may be partially attributed to non‐
adherence or improper use of inhalers. This study aimed to implement and assess 
hospital‐based pharmaceutical care services for asthmatic patients. A 12‐month, sin-
gle‐centre, randomized, controlled study was initiated in asthmatic adult patients who 
had been divided into either a control or intervention group. Patients in the control 
group received the usual care, and patients in the intervention group received patient 
counselling per study protocol that covered asthma knowledge, control, adherence to 
treatment and inhalation techniques. The main variables compared measurements at 
baseline with those at 6 and 12 months. A total of 192 patients completed the study 
protocol: 90 in the control group and 102 in the intervention group. The control 
group included 90 patients, and the intervention group included 102 patients. Over 
the course of the 12‐month follow‐up period, a significant difference was observed 
between intervention and control groups with respect to asthma control (38.2% 
vs 10.0%; P <  .001), mean correct inhalation technique (confidence interval [CI]: 
8.1, 7.8‐8.5 vs CI: 6.1; 5.6‐6.6; P = .01) and good medication adherence (60.7% vs 
50.0%, P = .02). There were 34% and 25% decreases in emergency room visits and 
hospital admissions, respectively, in the intervention group compared to the control 
group. This study emphasizes the importance of patient counselling in asthma man-
agement and the significant contribution that the pharmacist's intervention can have 
on asthma control.
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race, sex, socio‐economic factors and lifestyles.6,7 The two most 
often reported risk factors for asthma are cigarette smoking and 
genetic predisposition.8,9
In spite of the many options available for the treatment 
of asthma patients and deployment of evidence‐based guide-
lines in recent years, asthma control is still less than optimal 
as indicated by the fact that there have been no changes in 
disease‐related morbidity and mortality. Asthma is and will 
continue to be a major health problem worldwide.10,11
Many patients have suboptimal asthma control,12 and this 
suboptimal control can have implications on their health, 
healthcare costs and/or quality of life. Factors contributing to 
poor asthma control include behavioural and clinical factors. 
Such factors may include continuous exposure to asthma trig-
gers, poor treatment adherence and ineffective treatment deliv-
ery13 among others. Treatment adherence is a critical factor in 
chronic asthma disease control and prognosis.14 Improving pa-
tient adherence continues to be challenging, and well‐designed 
approaches are needed to improve patient outcome.15
Asthma treatment is highly dependent on inhalers. Proper in-
halation and device use were very crucial for effective for drug 
deposit to the lung. Several studies indicate that improper use 
of inhaler devices is common in clinical practice.8 Improper 
technique can contribute to poor asthma control.16 Most recent 
asthma guidelines1 emphasize the need for strategies that can im-
prove patient skills and knowledge for managing their disease.17
One notable method for improving adherence, knowledge 
and inhaler technique leading to improved asthma control is 
to integrate pharmacists into the healthcare system.
A previous review18 showed that pharmaceutical care 
services that utilize pharmacist‐based interventions had a 
positive on primary and secondary outcome, asthma control, 
adherence to medications, inhalation techniques, pulmonary 
function16 and severity.18 The change in pharmacists' practice 
should be emphasized in the hospital settings to be a more pa-
tient‐centred approach, through the provision of professional 
pharmacy services, supports and focuses on optimizing the 
use of medicines and improving health outcome.
To the best of our knowledge, this is the first pharmaceutical 
care service asthma‐based study in the West Bank. The main aim 
of this study was the implementation and assessment of a hos-
pital‐based pharmaceutical care service for asthmatic patients.
In this study, we evaluated the possible benefits of phar-
maceutical care services on asthma control, medication ad-
herence and inhalation technique in asthmatic adults.
2 |  MATERIALS AND METHODS
2.1 | Ethics approval
The Al‐Makassed Research Ethics Committee (reference 
PT‐15/June/2015) in addition to research and developmental 
approvals was obtained.
2.2 | Demography of the study area
The Al‐Makassed Charitable Society was officially estab-
lished in 1964 on the Mount of Olives in Jerusalem. It is a 
Palestinian non‐profit, non‐governmental organization that 
provides diversified humanitarian services in East Jerusalem. 
Al‐Makassed hospital is currently the leading medical centre 
in Jerusalem, providing secondary and tertiary health ser-
vices for all citizens of Palestine. The Al‐Makassed hospital 
is a 250‐bed hospital and is staffed by 750 employees.
2.3 | Study design
This study was a prospective, 12‐month, randomized, con-
trolled trial that was conducted in the outpatient clinic at Al‐
Makassed. Ethics approval was obtained from Al‐Makassed 
ethics committee, and patients gave written informed con-
sent. The study lasted from September 2015 to September 
2016, and the patients were randomized using computer 
software.
We targeted patients who were ≥18 years with persistent 
asthma, followed by their consultant, and undergoing in-
haled corticosteroid treatment (alone or combined with a 
long‐acting bronchodilator) as maintenance treatment for 
asthma control. Patients provided informed consent for study 
participation.
2.4 | Sample size and randomization
Minimum sample sizes were calculated according to previ-
ously described methods.19 Sample sizes were calculated in 
order to detect ≥20% differences in asthma control between 
study groups. Based on the previous studies and the litera-
ture, the minimum sample size was estimated to be 90 pa-
tients in each group with 95% confident level and 0.05 error 
level. In order to accommodate potential drop‐outs, 10% 
oversampling was done to yield 99 patients in each group. 
The participants in the study were randomly approached at 
the respiratory outpatient clinic, while they were waiting for 
their consultant. Patients were randomly allocated to inter-
vention or control (standard‐of‐care) groups using Minim 
software.20 Two hundred seventeen patients were recruited 
in this study. Figure 1 shows the study flow chart and the 
number of patients in each group at baseline and 6 months in 
addition to the 12‐month sample of 102 intervention group 
and 98 control group patients.
2.5 | Data collection and assessment
During clinic visits, data were collected by a well‐trained 
clinical pharmacist via structured, face‐to‐face interviews of 
the patients. Other relevant data were collected after patients 
underwent clinical examinations, which were performed by 
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attending physicians. A standard form was developed for 
data collection used for both groups.
Consultants evaluated their patients based on several parame-
ters: (a) predicted forced expiratory volume in 1 seconds (FEV1), 
(b) symptoms, (c) clinical data and (d) disease characteristics. In 
addition to clinical variables, other collected information included 
duration of asthma, a history of smoking, general practitioner 
(GP) and emergency department (ED) visits, and the number 
of asthma‐related admissions during the last year. Patients were 
asked questions pertaining to anti‐asthma medications that they 
had received in the last 12 months prior to inclusion in the study. 
In order to evaluate patient inhaler techniques, pharmacists used 
specific checklists specific for each study inhaler device type21 
both before and after providing training in correct inhaler use.
F I G U R E  1  Study design flow chart
270 patients receiving care were assessed for eligibility  
43 patients excluded 
30 patients did not meet the inclusion criteria as follows: 
     • 13 patients aged younger than 18 years 
     • 12 patients diagnosed with asthma less than 6 mos   
     • 5 patients did not take any control medications  
13 patients refused to participate 
227 eligible patients informed verbally about the 
study, and 217 patients signed consent form
Randomized to intervention arm 
111 patients received clinical pharmacy services 
Randomized to usual care arm 
106 patients received usual care services
Baseline data collection and intervention Baseline data collection 
Drop-outs 
4 patients were lost to 
follow-up:  
- 2 patients did not 
have outcome measures 
- 2 patients refused  
Drop-outs 
5 patients were lost to 
follow-up:  
- 3 patients did not 
have outcome measures 
- 2 patients refused  
6-mo outcome measures
107 patients’ data collection and intervention 
6-mo outcome measures
101 patients’ data collection and usual care 
Drop-outs 
5 patients were lost to 
follow-up:  
- 2 patients did not 
have outcome measures 
- 2 patients refused 
-  1 patient died  
Drop-outs 
 3 patients were lost to 
follow-up:  
- 1 patient 
transferred to other clinic 
- 2 patients refused  
12-mo outcome measures 
102 patients’ data collection and intervention 
12-mo outcome measures 
98 patients’ data collection and usual care  
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2.6 | Measurements
2.6.1 | Asthma control test (ACT)
The asthma control test (ACT) is a five‐item self‐adminis-
tered questionnaire developed for asthma control level assess-
ments.22 It evaluates the most recent 4‐week time period. Each 
item receives a score between 1 and 5 with total scores ranging 
5‐25 (higher is better). Levels of 20‐25 mean well‐controlled 
symptoms, 16‐19 not well‐controlled, and 5‐15 indicate very 
poorly controlled level (GINA 2018 classifications). An 
Arabic version of asthma control test in both Lebanon and 
Saudi Arabia has been translated and validated.23,24
Ten patients from Al‐Makassed hospital participated in a 
pilot study. The Cronbach's alpha was 0.81, showing good 
internal consistency, reliability and suitability for use in our 
setting.
2.6.2 | Medication adherence test
The Morisky Green Levine Medication Adherence Scale is 
commonly used to assess patient adherence to a drug regi-
men. It is a self‐administered questionnaire and comprised of 
four yes or no questions about medication taking history.25 
The Arabic version of the Morisky Green Levine tool is a 4‐
item questionnaire with four yes/no questions, which is used 
to explore the type of non‐adherence behaviour like: (a) for-
getting, (b) carelessness, (c) stopping medications when feel-
ing better and (d) stopping medications when feeling worse. 
According to the scoring system of the Morisky Green Levine 
adherence tool, scores can range from 0 to 4, with scores con-
sisting of 0, 1‐2, and 3‐4 that reflect high, medium and low 
adherence levels, respectively.26 Cronbach's alpha was 0.79 
for the instrument used in our study, indicating good internal 
consistency and reliability.
2.6.3 | Inhaler technique
A patient's inhaler technique was assessed by a very well‐
trained clinical pharmacist using placebo inhalers and stand-
ardized inhaler technique checklists that had been translated 
into Arabic by Basheti et al27 (see Appendix S1). Based on a 
literature review, nine steps for each type of device were de-
veloped (potential score ranged from 0 to 9). Of the total nine 
steps, four steps in turbuhaler device (TH) were considered 
essential steps and and three steps in pressurized metre dose 
inhaler (pMDI) and Accuhaler [Diskus] were considered es-
sential steps.28
2.6.4 | Intervention patient group
During the 12‐month follow‐up period, participants were 
approached three times during their consultation visits to 
the outpatient clinic. The clinical pharmacist ensured that 
patients received proper asthma management. Intervention 
patients were educated on an individual basis with respect 
to their asthma by the clinical pharmacist, therapy man-
agement, adherence to ICS, proper device and inhalation 
technique(s), and asthma symptom management. The 
clinical pharmacist also educated the participants about 
side effects, and when to use the rescue and maintenance 
medication(s).
The pharmacist taught and demonstrated inhaler tech-
niques. Patients were then asked to demonstrate the tech-
niques in order to ensure that they fully comprehended the 
proper technique for performing each technique. Moreover, 
follow‐up telephone calls were made by the clinical pharma-
cist to reinforce patient education and motivation in order to 
achieve their goals (between outpatient clinic appointments). 
At each visit, all intervention patients were provided with 
written action plans, written medication lists and their uses, 
and an asthma manual booklet.
2.6.5 | Control patient group
Control group participants received the usual care at the out-
patient clinic arranged by the hospital without any structured 
interventions by the clinical pharmacist.
During clinical visits, the participants completed the re-
quired forms that included demographic and clinical charac-
teristics, perceived asthma control and an asthma knowledge 
questionnaire, adherence and healthcare utilization at base-
line, 6‐ and 12‐month follow‐up periods.
2.6.6 | Data analysis
Data collected at baseline, 6‐ and 12‐month assessments 
were analysed using SPSS computer software version 22. 
Student's independent t test was used to investigate continu-
ous parameter comparability between groups (for variables 
with normal distribution). Mann‐Whitney U test was used 
for non‐normally distributed variables. Pearson's χ2 was used 
to examine categorical variables between study groups. The 
significance level was set at P ≤ .05.
This study was conducted in accordance with the Basic & 
Clinical Pharmacology & Toxicology policy for experimen-
tal and clinical studies 29
3 |  RESULTS
Two hundred seventeen patients (106 control and 111 inter-
vention patients) attending an outpatient asthma clinic at Al‐
Makassed hospital were recruited. In total 17 participants, nine 
and eight patients from the intervention and standard‐of‐care 
groups, respectively, did not complete the study (Figure 1). 
336 |   KHDOUR et al.
Therefore, a total of 200 patients (102 intervention and 98 
control) completed the 12‐month study period (Figure 1).
Baseline characteristics of the patients are reported in 
Table 1. Baseline characteristics were similar across socio‐
demographic, clinical and functional variables, includ-
ing age, sex, education status, smoking status, duration of 
asthma, asthma severity and pulmonary function. No clini-
cally significant, important differences were found in demo-
graphic or baseline characteristics between intervention and 
control groups.
3.1 | Asthma control test (primary outcome)
The mean asthma control test score was 12.2  ±  4.8 with 
the majority of patients in both groups (129, 59.3%) having 
very poorly controlled asthma (ie score 5‐15), 75 (34.6%), 
and some had moderate asthma control (ie score 16‐19), and 
only 13 (6.0%) of participants had well‐controlled asthma (ie 
scores 20‐25; Table 2). At baseline, very poorly controlled 
asthma scores indicated no significant differences between 
intervention and control groups (60.3% vs 58.4%; P = .66). 
The percentage of patients with well‐controlled asthma 
showed a significant increase in the intervention group at six 
months (43.0% vs 11.9%; P = .002) and at the 12‐month as-
sessment points (38.2% vs 10.2%; P = .001).
3.2 | Adherence to controlled medications 
(primary outcome)
Evaluation of maintenance asthma medications at baseline 
indicates that patients in the intervention group have the same 
pattern of adherence as the control group (Table 2) with no 
significant differences (P = .712). On the other hand, at the 
6‐ and 12‐month follow‐up visits, a higher percentage of pa-
tients in the intervention group exhibited significantly bet-
ter adherence to medication relative to control group patients 
(62.6% vs 50.0%; P < .001) and (62.7% vs 49.0%; P < .001), 
respectively.
3.3 | Inhaler technique
The mean scores of inhaler technique performance at base-
line were similar in the intervention and control groups (5.8 
vs 5.5; P = .66). In the intervention group, inhaler technique 
significantly improved compared to the control group at the 
6‐ (7.9 vs 5.7, P = .01) and 12‐month assessment points (8.1 
vs 6.1; P = .01).
3.4 | FEV1
Forced expiratory volume (per cent of predicted values post‐
bronchodilator) predicted values were reported at baseline, 
6‐ and 12‐month measurement points for both participant 
groups. No statistical differences in FEV1 mean values be-
tween the two groups at baseline, 6‐ and 12‐month measure-
ment points (Table 2) were seen.
3.5 | Health resources use
At the 1‐year measurements, participants allocated in the 
intervention group compared with control group had a sig-
nificant reduction in both emergency department visits (29 
vs 58; P = .01) and hospital admissions (15 vs 36; P = .03). 
For the GP visits (scheduled and unscheduled), no significant 
differences were observed (249 vs 221; P = .11) between the 
two groups (Table 3). This finding represents a 34% and 25% 
reduction in both emergency department and hospital admis-
sions, respectively.
T A B L E  1  Baseline characteristics of the population sample
Demographics
Intervention group 
(n = 111)
Control group
(n = 106)
Age (y)a
18‐40 45 (40.5%) 41 (38.7%)
41‐60 38 (34.3%) 42 (39.6%)
>60 28 (25.2%) 23 (21.6%)
Sexb
Male 48 (43.2%) 41 (38.6%)
Female 63 (56.8%) 65 (61.3%)
Education statusb
Primary 21 (18.9%) 18 (17.0%)
Secondary 38 (34.3%) 40 (37.7%)
College/University 52 (46.8%) 48 (45.3%)
Smoking statusb
Smoker 28 (25.2%) 31 (29.2%)
Non‐smoker 44 (39.6%) 50 (47.1%)
Ex‐smoker 39 (35.1%) 25 (23.6%)
Duration of Asthma 
(Y, SD)c
9.4 (± 4.4) 8.6 (± 4.1)
FEV1%c 72.4 (15.2) 69.2 ( 14.4)
Controller medica-
tion %
   
ICS 17 (15.3%) 22 (20.7%)
ICS + LABA 
combination
83 (74.7%) 75 (70.8%)
Theophylline 11 (9.9%) 12 (11.3%)
Leukotriene recep-
tor antagonists
3 (2.7%) 5 (4.7%)
LABA 2 (1.8%) 2 (1.9%)
Abbreviation: FEV1%, Forced expiratory volume (per cent of predicted values 
post‐bronchodilator).
aMann‐Whitney U test. 
bPearson's χ2 test. 
cStudent's t test. 
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4 |  DISCUSSION
The addition of pharmaceutical care in asthma management 
is a relatively new approach that integrates disease manage-
ment, adherence assessment and education of patients, in-
haler technique training, drug pharmacotherapy management 
and patient education. These skills need to be introduced in a 
systemic manner in everyday pharmacy practice for asthma 
and all other chronic diseases.
The results show that the asthma control at the 6‐ and 
12‐month assessment points significantly improved in pa-
tients who had been allocated to the educational interven-
tion group as compared to those in the standard‐of‐care 
group.
The study findings agree with findings from other pub-
lished reports.30 A study by Armour et al31 assessed asthma 
control using the ACT for patients receiving several (3‐4) 
asthma services during pharmacy visits. Results show a 32% 
and 38% increase in patients with good asthma control for 
the 3‐ and 4‐visit groups, respectively; in addition, decreases 
T A B L E  2  Clinical and humanistic outcomes during baseline, 6‐ and 12‐month follow‐up
Variables
Intervention Control
P‐value
Baseline
(n = 111)
6 mo
(n = 107)
12 mo
(n = 102)
Baseline
(n = 106)
6 mo
(n = 101)
12 mo
(n = 98)
% change FEV1 (95% CI) NA 10.9 (1.7‐18.8) 8.8 (2.1‐16.4) NA 6.8 (0.9‐12.1) 6.6 (1.1‐11.4) t1 .46a
t2 .55
Inhalation technique 
(range 1‐9)
5.1 (4.6‐6.1) 7.6 (7.0‐8.2) 7.1 (6.8‐8.5) 5.5 (5.1‐5.9) 5.7 (5.1‐6.0) 6.1 (5.6‐6.6) t0 .66b
t1 .01
t2 .01
Correct inhaler 
technique† 
22 (19.8%) 87 (81.3%) 80 (78.4%) 24 (22.6%) 32 (31.7%) 29 (29.6%) t0 .51c
t1 .01
t2 .01
Correct essential 
technique†† 
36 (32.4%) 94 (87.8%) 87 (85.3%) 39 (36.8%) 44 (43.6%) 39 (39.7%) t0 .66c
t1 .01
t2 .01
Asthma Control
Well‐controlled(20‐25) 6 (5.4%) 46 (43.0%) 39 (38.2%) 7 (6.6%) 12 (11.9%) 10 (10.2%) t0 .662c
Not well‐controlled
(16‐19)
38 (34.2%) 31 (29.0%) 33 (32.4%) 37 (34.9%) 30 (29.7%) 37 (37.7%) t1 .001
Very poor‐controlled
(5‐15)
67 (60.3%) 30 (28.0%) 30 (29.4%) 62 (58.4%) 59 (58.4%) 51 (51.1%) t2 .001
Adherence
High adherence
(0)
4 (3.6%) 20 (18.7%) 16 (15.7%) 6 (5.6%) 4 (3.9%) 5 (5.1%) t0 .712c
Moderate adherence
(1‐2)
57 (51.4%) 67 (62.6%) 64 (62.7%) 53 (50.0%) 51 (50.4%) 48 (49.0%) t1 .001
Non‐adherence
(3‐4)
50 (45.0%) 20 (18.7%) 22 (21.6%) 47 (44.3%) 46 (45.5%) 45 (45.9%) t2 .021
Abbreviations: FEV1%, forced expiratory volume in 1 s; NA, not applicable; t0 t1, t2, intervention vs control at baseline and at 6 and 12 mo, respectively.
aMann‐Whitney U test. 
bStudent's t test. 
cPearson's χ2 test. 
†Perform all nine steps correctly. 
††Essential step: if not performed correctly, little/no medication will reach the lung. 
T A B L E  3  Hospital admission, emergency department (ED) visits 
and general practitioner (GP) visits during the 12‐month follow‐up 
period
Variable
Control
(n = 98)
Intervention
(n = 102) P‐Value
Gp Visit 221 249 .11† 
ED Visit 58 29 .01† 
Hospital admission 36 15 .03† 
Hospital Days 124 49 .001* 
Abbreviation: ED, Emergency department.
†Pearson's χ2 test. 
*Mann‐Whitney test. 
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in the mean ACT scores of 0.57 and 0.56, respectively, were 
observed.
In the present study, there was a high proportion of pa-
tients with very poorly controlled asthma and smoking sta-
tus; similarly, Gracia et al32 found in their study that 21% of 
the participants were current smokers. Mehuys et al33 mea-
sured the effects of education intervention on asthma control 
using ACT and found that patients benefiting the most from 
intervention were the ones with insufficient baseline asthma 
control. On the other hand, the present study shows positive 
impacts of intervention over a wider range of patients at both 
6‐ and 12‐month assessment points. A pharmacist‐provided 
pharmaceutical care service led to significant improvement 
in self‐management by providing an asthma action plan, and 
other self‐care activities such as such as avoiding exposure to 
triggers and smoke.
As previously suggested, the fact that the education‐based 
intervention may have a more significant impact on patients 
with poor asthma control suggests that identifying these pa-
tients would allow for better asthma management and proba-
bly lower costs over time.34
According to GINA recommendations, interventions de-
livered to patients need to be tailored to a patient's current 
asthma control. For example, in the current study, adherence 
education was individualized, taking into account an assess-
ment of concerns and beliefs about asthma treatment. Patient 
counselling had a significant effect on adherence behaviours 
at all assessment points. In an earlier study by Gallefoss and 
Bakke35 that included asthmatic and COPD patients, the phar-
macist counselling included two‐hour educational sessions and 
tailored session for needed individuals. The study found that 
patients who received the educational intervention presented 
higher adherence (>75% adherence) than those who did not.
Inhaler training included physical demonstrations in ad-
dition to written and verbal counselling that were shown to 
be effective in other studies.16,36 The intervention group had 
more patients who were using correct inhaler techniques 
throughout the study period.
Proper inhalation technique and medication compliance 
are essential factors and indicators for successful asthma 
treatment, and the fact that both parameters improved in 
the intervention group most likely contributed to enhanced 
asthma control. Unfortunately, in many clinical settings, 
neither training nor assessment of inhaler technique is per-
formed, thus increasing the risk of inhaler device misuse.37
Hospital and ED admissions are the main drivers of cost 
in chronic disease management. An important finding in 
this study was the 36% and 25% reductions in ED visits and 
hospital admissions, respectively, in the intervention group 
at the 12‐month measurement point. An important finding 
that a higher proportion of moderate and severe participants 
were presented to the ED and admitted to the hospital in-
dicates that tailored interventions should be targeted those 
moderate‐to‐severe cases. It is worth to note that asthma ED 
visits and hospital admission impose a significant economic 
cost and expenditure to the health system.
Three other studies37-39 reported a significant decrease 
in ED visit and hospital admissions when patients undertook 
self‐management and educational interventions. In a system-
atic review of twelve studies (involving 1954 adults), Tapp et 
al reported that education significantly reduced subsequent ED 
visits with relative risk reduction by 0.5. Boyd et al reported 
that educational intervention in asthmatic patients significantly 
reduced the risk of subsequent hospital admissions and ED vis-
its with relative risk by 0.79 and visits to emergency department 
with relative risk by 0.73 compared to controls. Paptist et al 
evaluated a self‐management programme for adult asthmatic 
patients for 6 and 12 months and found a significant reduction 
in healthcare utilization in the self‐management group.
4.1 | Study limitations
The study presented some limitations. Firstly, the study used 
self‐report questionnaires to assess control and compliance 
to medications; this method has the disadvantages of recall 
bias. Secondly, the study covered only one hospital in East 
Jerusalem, which may have to some extent limited the overall 
generalizability of the findings. Further research is needed 
with more hospitals and medical centres in order to evalu-
ate long‐term clinical, humanistic and economic impacts of 
pharmaceutical care services.
5 |  CONCLUSION
Our study confirms other results described in the literature in-
dicating that a trained pharmacist who provides pharmaceuti-
cal care can assume a positive role in facilitating effective 
treatment and increase controlled asthma patients compared 
to the standard‐of‐care. A well‐structured pharmaceutical 
care delivery system in the hospital facilitates improvements 
in patient knowledge, medication adherence, inhaler tech-
niques and asthma control. As such, hospital pharmacists 
need to be properly trained to assess asthma patients and 
provide the education needed to address the individual chal-
lenges of the condition and its management.
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